Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Pro
by from Morbidity and Mortality Weekly Report (MMWR) on (#68YCH)
This report describes up to 4 months of protection against COVID-19 among children aged 3-5 and 3-4 year who received monovalent primary series vaccinations.